| 摘要 |
The present invention is concerned with novel benzo¢e!-isoindoles and benzo¢h!isoquinolines. Since the compounds in accordance with the invention can bind to serotonin receptors (5HT2), they are especially suitable for the treatment or prevention of central nervous disorders such as depressions, bipolar disorders, anxiety states, sleep and sexual disorders, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or pain of a different kind, personality disorders or obsessive-compulsive disorders, social phobias or panic attacks, mental organic disorders, mental disorders in childhood, aggressivity, age-related memory disorders and behavioural disorders, addiction, obesity, bulimia, etc., nervous system damage caused by trauma, stroke, neurodegenerative diseases, etc.; cardiovascular disorders such as hypertension, thrombosis, stroke, etc; and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility. |
